Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.38 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.38 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.38 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.38 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.38 |
| ▸ | TFPI2 | P48307 | 1/20 | 0.38 |
| ▸ | HPGDS | O60760 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25229548 | 0.82 | ALDH1A1 (0.41) | ALDH1A1HPGDF2GLAKMT2A | |
| SCHEMBL29248231 | 0.78 | PTGDR2 (0.43) | ALDH1A1HPGDHTT | |
| SCHEMBL23327801 | 0.76 | SLC22A12 (0.41) | ALDH1A1HPGDF2GLAMTNR1A | |
| SCHEMBL30621458 | 0.74 | ALDH1A1 (0.39) | ALDH1A1HPGDF2GLAKMT2A | |
| SCHEMBL30297606 | 0.73 | TFPI2 (0.57) | ALDH1A1HPGDKMT2AMTNR1BMTNR1A | |
| SCHEMBL5569918 | 0.73 | TFPI2 (0.57) | ALDH1A1HPGDKMT2AMTNR1BMTNR1A | |
| SCHEMBL21353441 | 0.72 | GRIN2B (0.35) | ALDH1A1 | |
| SCHEMBL12065347 | 0.71 | KDM4E (0.57) | ALDH1A1HPGD | |
| SCHEMBL31200192 | 0.70 | PIK3C3 (0.52) | MTNR1BMTNR1A | |
| SCHEMBL3249823 | 0.70 | TUBB1 (0.62) | ALDH1A1HPGDMTNR1BMTNR1ATFPI2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200207759-A1 | NEW PROPANAMINE DERIVATIVES FOR TREATING PAIN AND PAIN RELATED CONDITIONS | ESTEVE PHARMACEUTICALS, S.A (ES) | 2020-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200207759-A1 | NEW PROPANAMINE DERIVATIVES FOR TREATING PAIN AND PAIN RELATED CONDITIONS | CACNA1B, CACNA1G, ADRB2 | ALDH1A1 837/4885HPGD 1093/4885F2 2397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.